Investigational drug · Phase 2
HRS-7249
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hyperlipidemia.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "HRS-7249"
First trial start
2025
Aug 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-7249", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hyperlipidemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-7249" as an intervention, largest first.
- A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With HypertriglyceridemiaPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07799688 · 400 participants (planned) · Start Sep 11, 2026 · Primary completion Oct 15, 2028
Drug: HRS-7249 Injection; HRS-7249 Injection · For: Hyperlipidemia
Sites: Jinan, China; Shanghai, China
- A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With HyperlipidemiaPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07100418 · 224 participants · Start Aug 12, 2025 · Primary completion Sep 2026
Drug: HRS-7249 Injection; Sodium Chloride Injection · For: Hyperlipidemia
Sites: Shanghai, China
- Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07308392 · 119 participants · Start Feb 25, 2026 · Primary completion Jun 2027
Drug: HRS-7249 injection set; SHR-1918 injection set and 2 more · For: Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Sites: Nanjing, China
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06541457 · 48 participants · Start Aug 15, 2024 · Primary completion Jul 30, 2025
Drug: HRS-7249 injection; Placebo · For: Hyperlipidemia
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hyperlipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.